DGIdb - ALVESPIMYCIN Drug Record

ALVESPIMYCIN chembl:CHEMBL383824 Antineoplastic

Alternate Names:

NSC-707545
ALVESPIMYCIN

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(1 More Sources)

Publications:

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature
Rodina A et al., 2007, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer., Nat Chem Biol
Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.

ALVESPIMYCIN HSP90AB1

Interaction Score: 1.25

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545

Novel drug target Novel Target

PMIDs:
17603540

Sources:
DTC TdgClinicalTrial
ALVESPIMYCIN HSP90AA1

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545

PMIDs:
17139284 17016423 10592235

Sources:
TdgClinicalTrial
ALVESPIMYCIN MET

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26483207

Sources:
JAX-CKB
ALVESPIMYCIN TP53

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Alvespimycin + Vorinostat

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
26009011

Sources:
JAX-CKB

TdgClinicalTrial: ALVESPIMYCIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:
DTC: ALVESPIMYCIN
- Version: 02-September-2020
Alternate Names:

CHEMBL383824 ChEMBL Drug ID

Drug Info:

Publications:

Rodina A et al., 2007, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer., Nat Chem Biol

JAX-CKB: Alvespimycin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.

Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature

TALC: ALVESPIMYCIN
- Version: 12-May-2016
Alternate Names:

ALVESPIMYCIN Primary Drug Name

ALVESPIMYCIN Drug Generic Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL383824
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545
Novel drug target	Novel Target

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	predicted – sensitive
Approval Status	Preclinical - Cell line xenograft

combination therapy	Alvespimycin + Vorinostat
Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive

ALVESPIMYCIN Drug Record

ALVESPIMYCIN chembl:CHEMBL383824 Antineoplastic

Alternate Names:

Drug Info:

Publications:

ALVESPIMYCIN HSP90AB1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545 Novel drug target Novel Target

PMIDs: 17603540

Sources: DTC TdgClinicalTrial

ALVESPIMYCIN HSP90AA1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545

PMIDs: 17139284 17016423 10592235

Sources: TdgClinicalTrial

ALVESPIMYCIN MET

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type predicted – sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 26483207

Sources: JAX-CKB

ALVESPIMYCIN TP53

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Alvespimycin + Vorinostat Indication/Tumor Type Advanced Solid Tumor Response Type sensitive

PMIDs: 26009011

Sources: JAX-CKB

TdgClinicalTrial: ALVESPIMYCIN

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

DTC: ALVESPIMYCIN

Alternate Names: CHEMBL383824 ChEMBL Drug ID

Drug Info:

Publications: Rodina A et al., 2007, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer., Nat Chem Biol

JAX-CKB: Alvespimycin

Alternate Names:

Drug Info:

Publications: Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res. Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature

TALC: ALVESPIMYCIN

Alternate Names: ALVESPIMYCIN Primary Drug Name ALVESPIMYCIN Drug Generic Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL383824

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545

Novel drug target Novel Target

PMIDs:
17603540

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545

PMIDs:
17139284 17016423 10592235

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26483207

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Alvespimycin + Vorinostat

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
26009011

Sources:
JAX-CKB

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL383824 ChEMBL Drug ID

Publications:

Rodina A et al., 2007, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer., Nat Chem Biol

Publications:

Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.

Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature

Alternate Names:

ALVESPIMYCIN Primary Drug Name

ALVESPIMYCIN Drug Generic Name